L-ornithine L-aspartate in bouts of overt hepatic encephalopathy

Abstract

High quality data on efficacy of L-Ornithine L-Aspartate (LOLA) in cirrhotics with bouts of overt hepatic encephalopathy (OHE) is missing. We aimed to evaluate the efficacy of intravenous LOLA in reversal of bouts of OHE in cirrhotics. In this prospective double-blind randomized placebo controlled trial conducted at two tertiary care institutes in India, 370 cirrhotics with bouts of OHE were screened. After exclusion, 193 (52.16%) patients were randomized to receive either intravenous infusions of LOLA (n=98), 30 grams daily or Placebo (n=95) for 5 days. Standard of care treatment (including Lactulose and Ceftriaxone) was given in both groups. Randomisation was done centrally through the http://ift.tt/2vaSf2h. All study personnel were blinded to the treatment assignment. Fasting venous ammonia levels were estimated daily from 0-5 days. Serum Tumor Necrosis Factor α, Interleukins, hemogram, liver and renal function tests were performed at day 0 and 5. Primary outcome was mental state grade at day 5 of treatment. This article is protected by copyright. All rights reserved.

http://ift.tt/2w3bYgO